Diagnosis and classification of sporadic inclusion body myositis (sIBM)

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 363-366

  Catalan M ^a   Selva O'Callaghan, A ^b   Grau, J M ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Inclusion body; Inflammation; Myopathy; Myositis

Indexed keywords

ACUTE PHASE PROTEIN; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CREATINE KINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RHEUMATOID FACTOR;

AUTOIMMUNE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; HUMAN; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE WEAKNESS; PATHOGENESIS; PROGNOSIS; REVIEW; SPORADIC INCLUSION BODY MYOSITIS;

INCLUSION BODY; INFLAMMATION; MYOPATHY; MYOSITIS;

AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PREVALENCE; PROGNOSIS;

EID: 84896317310     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.016     Document Type: Review

References (28)

1. Oflazer P.S., Deymeer F., Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases 2011, 30.
2. Badrising U.A., Maat-Schieman M., van Duinen S.G., Breedveld F., van Doorn P., van Engelen B., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000, 55:1385-1387.
3. Suzuki N., Aoki M., Mori-Yoshimura M., Hayashi Y.K., Nonaka I., Nishino I. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. Arch Neurol 2012, 259:554-556.
4. Needham M., Corbett A., Day T., Fabian V., Mastaglia F. Prevalence and diagnosis of sporadic inclusion body myositis (sIBM) in Western Australia. Neuromuscul Disord 2007, 17:850-851.
5. Needham M., Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007, 6:620-631.
6. Dalakas M.C. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006, 2:437-447.
7. Yunis E.J., Samaha F.J. Inclusion body myositis. Laboratory investigation; a journal of technical methods and, pathology 1971, 25:240-248.
8. Temiz P., Weihl C.C., Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009, 278:25-29.
9. Choi Y.C., Park G.T., Kim T.S., Sunwoo I.N., Steinert P.M., Kim S.Y. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2. J Biol Chem 2000, 275:8703-8710.
10. Selva-O'Callaghan A., Casellas F., de Torres I., Palou E., Grau-Junyent J.M., Vilardell-Tarres M. Celiac disease and antibodies associated with celiac disease in patients with inflammatory myopathy. Muscle & nerve. 2007, 35:49-54.
11. Garlepp M.J., Laing B., Zilko P.J., Ollier W., Mastaglia F.L. HLA associations with inclusion body myositis. Clin Exp Immunol 1994, 98:40-45.
12. Jain A., Sharma M.C., Sarkar C., Bhatia R., Singh S., Handa R. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch Pathol Lab Med 2007, 131:1070-1076.
13. Murphy M.P., Golde T.E. Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?. Neurology 2006, 66:S65-S68.
14. Levacic D., Peddareddygari L.R., Nochlin D., Sharer L.R., Grewal R.P. Inclusion-body myositis associated with Alzheimer's disease. Case Rep Med 2013, 2013:536231.
15. Askanas V., Engel W.K. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008, 116:583-595.
16. Mendell J.R., Sahenk Z., Gales T., Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991, 48:1229-1234.
17. Salajegheh M., Pinkus J.L., Taylor J.P., Amato A.A., Nazareno R., Baloh R.H., et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009, 40:19-31.
18. Ritson G.P., Custer S.K., Freibaum B.D., Guinto J.B., Geffel D., Moore J., et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci Off J Soc Neurosci 2010, 30:7729-7739.
19. Greenberg S.A. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012, 25:630-639.
20. Salajegheh M., Lam T., Greenberg S.A. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 2011, 6:e20266.
21. Koffman B.M., Rugiero M., Dalakas M.C. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle & nerve. 1998, 21:115-117.
22. Bielsa S., Madronero A.B., Grau J.M., Porcel J.M. Inclusion-body myositis associated with systemic sclerosis. Med Clin (Barc) 2007, 128:278.
23. Badrising U.A., Schreuder G.M., Giphart M.J., Geleijns K., Verschuuren J.J., Wintzen A.R., et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004, 63:2396-2398.
24. Ray A., Amato A.A., Bradshaw E.M., Felice K.J., DiCapua D.B., Goldstein J.M., et al. Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLoS ONE 2012, 7:e46709.
25. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
26. Zschuntzsch J., Voss J., Creus K., Sehmisch S., Raju R., Dalakas M.C., et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and beta-amyloid in the muscle. Arthritis Rheum 2012, 64:4094-4103.
27. Quartuccio L., De Marchi G., Scott C.A., Ferraccioli G., Beltrami C.A., De Vita S. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007, 25:246-251.
28. Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012, 14:244-251.